Imatinib, a tyrosine kinase inhibitor of PDGFR, c-KIT, and BCR-ABL, improved sensitivity to chemotherapy in vitro, but without showing a meaningful antitumor activity in high-grade gliomas in clinical trials [60,82]. The gene discussed is PDGFRB; the disease is glioma.